A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients

To evaluate the healing rate and safety of Lafutidine in erosive esophagitis

Inclusion Criteria:

• Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux esophagitis according to the Los Angeles classification

Exclusion Criteria:

• Gastric or duodenal ulcers (excluding ulcer scars)
• Concurrent presence of Barrett's esophagus
• A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks
• Other conditions considered by the attending physician to potentially affect the assessment of efficacy and safety